All Activity

Great job on this guide. The content is concise, practical, and covers everything needed without being overwhelming. IPTV Quebec

A coalition of anti-marijuana groups and a cannabis-focused biopharmaceutical corporation are asking a federal appeals court to overturn a judge’s dismissal of their lawsuit challenging a new Trump administration initiative to cover up to $500 worth of hemp-derived products each year for eligible Medicare patients. Last month, Judge Trevor N. McFadden dismissed the challenge to the program that’s implemented by the Centers for Medicare & Medicaid Services (CMS) that focuses largely on CBD but also allows a certain amount of THC in products. He ruled that prohibitionist groups and activists, led by Smart Approaches to Marijuana (SAM), as well as a cannabis-focused biopharmaceutical corporation MMJ International Holdings and its subsidiaries, “have not established standing to bring this case.” Now, the plaintiffs are appealing to the U.S. Court of Appeals for the District of Columbia Circuit. “Notice is hereby given that Plaintiffs Smart Approaches to Marijuana, Cannabis Industry Victims Educating Litigators, Hillsborough County Anti-Drug Alliance, MMJ International Holdings, Inc., MMJ Biopharma Cultivation, Inc., and MMJ Biopharma Labs, Inc. hereby appeal to the United States Court of Appeals for the District of Columbia Circuit from the judgment of this court entered on May 22, 2026 in favor of Defendants against said Plaintiffs,” the short document filed on Friday says. SAM CEO Kevin Sabet said in a press release that “this fight is far from over, and we will not stand by while CMS allows for non-FDA-approved products to be given out to seniors.” “This program puts CMS in bed with Big Tobacco and Big Weed, and it puts American seniors at risk,” he argued. “CMS has a mandate to promote public health, and this program would degrade it. This move would not only put seniors at risk but also send the wrong message to the American people about the safety of these products, which have been found to have a whole host of negative side effects.” In April, lawyers for Health and Human Services Sec. Robert F. Kennedy Jr. and CMS Director Mehmet Oz filed a brief arguing that the anti-cannabis organizations that filed the suit against the Medicare hemp coverage policy do not have standing to bring the case. Outside of the challenge to the CMS hemp program, SAM and MMJ filed separate lawsuits challenging the Trump administration’s move to federally reschedule marijuana. Beyond the advocacy organizations and MMJ, the CMS hemp case involves individual plaintiffs, including anti-marijuana lawyer David Evans, who claims he had standing to challenge the new Substance Access Beneficiary Engagement Incentive (BEI) as a Medicare recipient. Previously, McFadden had rejected the plaintiffs’ request for a temporary restraining order to halt the program from launching on April 1. Notably, the government’s motion to dismiss the case says it was prepared in part by Matthew Zorn, a lawyer for HHS who before taking on the federal job led numerous cases suing government agencies on behalf of plaintiffs seeking marijuana and drug policy reform. The CMS initiative comes after President Donald Trump signed an executive order in December calling on the attorney general to finalize a rule federally rescheduling marijuana, which is now underway, that also contained components to “improve access” to full-spectrum CBD products. Under the program, inhalable preparations are not allowed, and products can contain no more than 0.3 percent delta-9 THC by dry weight and can have up to 3 milligrams of total THC per serving. The THC limit could potentially change if a law the president signed late last year takes effect as scheduled this November. That policy would strictly limit the types of cannabis products that are currently permitted under the 2018 Farm Bill that Trump signed in his first term, expressly prohibiting hemp derivatives containing more than 0.4 milligrams of total THC per container. This week, the White House called on Congress to take action to amend the planned ban to maintain legal access to hemp-derived full-spectrum CBD products. In a brief in the CMS hemp lawsuit, federal agencies noted that “CMS does not pay for hemp products under the BEI.” “The participating provider furnishes eligible products at its own cost, subject to the $500 annual cap per beneficiary. The BEI operates within the shared-savings framework that defines the underlying models. If a provider’s investment in beneficiary engagement reduces the beneficiary’s total cost of care, the provider and CMS share in the resulting savings. If it does not, the provider absorbs the loss. No new federal appropriation is involved. No new entitlement is created. The BEI is, at its core, a decision by willing providers that a particular intervention can reduce downstream claims.” Meanwhile, the White House Office of Management and Budget recently held a series of meetings about a Food and Drug Administration (FDA) CBD products enforcement policy. FDA also issued guidance making clear that it does not intend to interfere with implementation of the Medicare hemp-derived products coverage plan. CMS separately finalized a rule that will allow coverage of some hemp products as specialized, non-primarily health-related benefits through Medicare Advantage plans. Read the filing appealing the dismissal of the lawsuit challenging the Medicare hemp program below: Photo courtesy of Kimzy Nanney. The post Anti-Marijuana Groups And Pharma Company Ask Court To Revive Lawsuit Challenging Medicare Hemp Coverage Program appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Virginia officials in the administration of Gov. Abigail Spanberger (D) and lawmakers who sponsored a bill to legalize recreational marijuana sales that the governor vetoed last month have met recently to discuss the possibility of enacting the reform through budget legislation that is due to be passed soon. The sides are getting closer to reaching a deal, several sources said. “The negotiation with the governor has been very fruitful and it is clear that we have made a great deal of progress,” Del. Paul Krizek (D), who sponsored the House of Delegates version of the cannabis sales legislation, told Marijuana Moment on Friday. A spokesperson for Spanberger said the governor “has made clear that she continues to support setting up a legal retail marketplace for cannabis that prioritizes the health and safety of Virginians, protects communities and consumers and operates with clear enforcement and regulatory authority.” The governor and the sponsors of the legalization legislation “share these same goals, and she looks forward to moving this across the finish line together,” the spokesperson told Marijuana Moment. Lawmakers passed the cannabis sales bills in March, but the governor then suggested changes to the legalization proposal—including delaying the start date for sales by six months, increasing taxes and instituting new criminal penalties for cannabis consumers. The legislature in April declined to take up the amendments during a one-day reconvened session, however, effectively rejecting them. Spanberger then issued a veto. Spanberger herself has sat down in recent days with Krizek and Sen. Lashrecse Aird (D), who sponsored the Senate version of the legislation, two sources familiar with the negotiations told Marijuana Moment. Krizek also met on Thursday with an administration official to discuss the issue, the sources, who asked not to be named, said. Full details of a potential compromise on the issue between lawmakers and the governor are not yet clear, but sources indicated that the timeline for launching the cannabis market would have to be moved back at least somewhat from the date included in the now-vetoed bill. They also suggested that it is unlikely any new penalties would be as harsh as those previously proposed by the governor. Aird did not immediately respond to Marijuana Moment’s request for comment for this story. Other areas of disagreement between the cannabis legislation as passed by lawmakers and the governor’s proposed amendments that will need to be negotiated before a final deal is reached include tax rates, the number of dispensaries that will be allowed to operate and legal possession limits for consumers. Following Spanberger’s veto, top lawmakers have been openly discussing the possibility of including provisions to legalize adult-use cannabis sales in still-outstanding budget legislation that they are due to pass by July 1. The effort to keep the issue alive was a topic of discussion earlier this week at the first meeting of the legislature’s Joint Commission to Oversee the Transition of the Commonwealth into a Cannabis Retail Market since the governor’s move to kill the previous proposal to regulate adult-use marijuana sales. The governor, meanwhile, is continuing to try to publicly explain her veto—including by saying it is her view that “taking a little bit longer” to launch the market is not something she sees as “negative” because it is more important to get the details right than to do it fast. A recent survey found that bipartisan majorities of Virginia voters wanted Spanberger to sign the cannabis legislation into law, and that they specifically disagreed with her desire to slow the launch timeline for legal sales. The governor recently acknowledged in a separate interview that “a lot of people are not pleased” with her veto of the cannabis legislation. “Friends and family are displeased as well,” she said. Spanberger has repeatedly responded to criticism of her cannabis amendments from the bill sponsors and advocates by saying the suggested changes came after she spoke to the leaders of other states that have already implemented adult-use marijuana markets. A spokesperson for Spanberger declined to name any other governors she talked to about cannabis in response to a question from Marijuana Moment, however. The governor separately recently sought to explain her veto in an earlier interview, reiterating that she supports launching a legal cannabis market but worried about what she called a “rushed timeline” and “far more stores across Virginia” than she thinks are appropriate. Prior to vetoing the cannabis commerce bill, the governor did sign separate legislation to provide resentencing relief for people with past cannabis convictions. Personal marijuana possession and home cultivation of marijuana has been legal in Virginia since 2021, but then-Gov. Glenn Youngkin (R) twice vetoed bills to provide consumers with a way to legally purchase regulated adult-use cannabis. Aird and Krizek, the sponsors of the legalization bills, had urged colleagues to vote against the governor’s amendments—even if that meant risking a veto from Spanberger when the legislation returned to her desk, which has now occurred. Here are the other key details of the cannabis bills—SB 542 and HB 642—as approved by lawmakers and with the governor’s suggested amendments: Lawmakers voted to allow adults to be able to purchase up to 2.5 ounces of marijuana in a single transaction, or up to an equivalent amount of other cannabis products as determined by regulators. That would represent an increase from the limit in current law of 1 ounce. The governor, however, wanted the amount increased to only 2 ounces. Under the legislature’s plan, legal sales could begin on January 1, 2027, but the governor proposed to push that back to July 1, 2027. Lawmakers voted to impose an excise tax of 6 percent on cannabis sales as well as a 5.3 percent retail sales and use tax, while allowing municipalities to set an additional local tax of up to 3.5 percent. The governor’s plan was largely the same, though it would have increased the excise tax to 8 percent starting on July 1, 2029. Under the legislation as approved by lawmakers, revenue would have been distributed to the Cannabis Equity Reinvestment Fund (30 percent), early childhood education (40 percent), the Department of Behavioral & Developmental Health Services (25 percent) and public health initiatives (5 percent). The governor, however, wanted to put all revenue into the general fund while earmarking it “for purposes such as early childhood education, behavioral health, public health awareness, prevention, treatment, and recovery services, workforce development, reentry, indigent criminal defense, and targeted reinvestment in historically disadvantaged communities.” The Virginia Cannabis Control Authority would have overseen licensing and regulation of the new industry, and would have also taken on oversight of hemp, which is currently under the Department of Agriculture and Consumer Services. Local governments could not have opted out of allowing marijuana businesses to operate in their area. Delivery services would have been allowed. Serving sizes would have been capped at 10 milligrams THC, with no more than 100 mg THC per package. The governor proposed to make public marijuana use a class 4 criminal misdemeanor instead of civil violation punishable by a $25 fine as under current law. She also wanted to make possessing cannabis by people under the age of 21 a class 1 misdemeanor, punishable with a mandatory minimum fine of $500 or 50 hours of community service, as well as the suspension of drivers licenses for at least six months. Illegally selling or distributing 50 pounds or more of marijuana would have been a class 2 felony punishable by life in prison. The governor sought to eliminate support for the Cannabis Equity Reinvestment Fund. Existing medical cannabis operators could have entered the adult-use market if they pay a licensing conversion fee that was set at $10 million. Cannabis businesses would have had to establish labor peace agreements with workers. As passed by lawmakers, the bill would have directed a legislative commission to study adding on-site consumption licenses and microbusiness cannabis event permits that would allow licensees to conduct sales at venues like farmers markets or pop-up locations, but the governor proposed to remove that language. A coalition of cannabis reform organizations sent the governor a letter urging her not to veto the sales legalization legislation even though her amendments were rejected. “Together, these bills address the real issues surrounding cannabis in the Commonwealth today: an already-existing, unregulated marijuana market operating openly across the state while consumers, communities, and law enforcement are left without the protections of a legal framework,” the groups wrote. “Let’s be clear: these bills do not create a marijuana market in Virginia. That market already exists,” the letter said. “What these bills do is replace today’s predatory and unaccountable illicit operators with a regulated marketplace, enforceable rules, oversight, product safeguards, age verification, and the strict consumer safety standards already in use for Virginia medical cannabis.” The letter was signed by Virginia NORML, Marijuana Justice, Virginia Cannabis Association, Marijuana Policy Project and other groups. Separately, a coalition of hemp businesses that joined with a major alcohol retailer in asking Spanberger to veto the marijuana bill before she did so said the move presents an “opportunity” to craft better cannabis policy. Meanwhile, the governor signed several other reform bills this session—including measures to protect the parental rights of marijuana consumers and allow patients to access medical cannabis in hospitals. The post Virginia Lawmakers And Governor Meet To Discuss Marijuana Sales Legalization Compromise That Could Pass This Month appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Congratulations to Erica Fuller on being recognized as Tokeativity's Member of the Month! Your dedication, authenticity, and contributions to the community are truly inspiring. It's wonderful to see your hard work and passion being celebrated. Wishing you continued success and looking forward to seeing all the amazing things you'll accomplish next! You can also take note about AI servcies like Ai receptionist Evansville and Virtual receptionist Kansas City

A congressional panel has approved annual spending legislation that would affirmatively block federal workers’ compensation programs from covering medical marijuana—even in light of the Trump administration’s move to reschedule cannabis. The House Appropriations Subcommittee on Labor, Health and Human Services, Education, and Related Agencies on Friday voted 11-7 to advance the Fiscal Year 2027 bill that contains several marijuana- and drug policy-related provisions. One section says that no funding provided to the Department of Labor under the measure can be used to “authorize, provide, reimburse, or otherwise recognize marijuana or any cannabis-derived substance as a compensable medical treatment or benefit” under any federal workers’ compensation program—”regardless of any change in the scheduling of marijuana” under the Controlled Substances Act (CSA). “SEC. 532. None of the funds made available by this Act may be used by the Department of Labor, including the Office of Workers’ Compensation Programs, to authorize, provide, reimburse, or otherwise recognize marijuana or any cannabis-derived substance as a compensable medical treatment or benefit under any Federal workers’ compensation program, including the Federal Employees’ Compensation Act, regardless of any change in the scheduling of marijuana under the Controlled Substances Act. Nothing in this section shall be construed to require or permit reimbursement for marijuana under any Federal workers’ compensation program.” Trump administration in April announced that it was moving state-licensed medical cannabis, as well as any cannabinoid products approved by the Food and Drug Administration, to Schedule III, where WNBA’s prohibition would presumably no longer apply. Broader reclassification of marijuana to Schedule III will be the topic of a hearing scheduled to begin later this month. The bill that is advancing also contains a rider that blocks the use of funds for “any activity that promotes the legalization of any drug or other substance included in schedule I” of the Controlled Substances Act. “SEC. 509. (a) None of the funds made available in this Act may be used for any activity that promotes the legalization of any drug or other substance included in schedule I of the schedules of controlled substances established under section 202 of the Controlled Substances Act except for normal and recognized executive-congressional communications. (b) The limitation in subsection (a) shall not apply when there is significant medical evidence of a therapeutic advantage to the use of such drug or other substance or that federally sponsored clinical trials are being conducted to determine therapeutic advantage.” The provision has been included in federal spending legislation since the 1990s. Rep. Alexandria Ocasio-Cortez (D-NY) in past years has attempted to get that language deleted by arguing that it impedes research on psychedelics, but her amendments have been defeated. Finally, the legislation as approved by the subcommittee contains a rider restricting the use of funds for syringe exchange programs and a prohibition on support for safe consumption sites for illegal drugs. “SEC. 525. Notwithstanding any other provision of this Act, no funds appropriated in this Act shall be used to purchase sterile needles or syringes for the hypodermic injection of any illegal drug: Provided, That such limitation does not apply to the use of funds for elements of a program other than making such purchases if the relevant State or local health department, in consultation with the Centers for Disease Control and Prevention, determines that the State or local jurisdiction, as applicable, is experiencing, or is at risk for, a significant increase in hepatitis infections or an HIV outbreak due to injection drug use, and such program is operating in accordance with State and local law: Provided further, That none of the funds appropriated in this Act may be used for the operation of a supervised drug consumption facility that permits the consumption onsite of any substance listed in schedule I of section 202 of the Controlled Substances Act (21 U.S.C. 812).” Earlier this week, the House Appropriations Committee approved a separate spending bill and attached report that directs federal officials to continue requiring government employees and safety-sensitive workers such as truck drivers and airline pilots to be drug tested for marijuana, “regardless of any future changes to the legal status or scheduling.” The panel also voted last month to advance a provision that, if enacted, would prevent federal officials from taking further steps to carry out marijuana rescheduling. That funding bill also contains an updated version of a longstanding rider that since 2014 has protected state medical cannabis programs from federal interference. The committee report attached to that legislation also contains a number of cannabis-related provisions, including one calling on the Drug Enforcement Administration (DEA) and Food and Drug Administration (FDA) to address the “proliferation of Federally unregulated ingestible, inhalable, and topical products that contain intoxicating cannabinoids” and that “threaten consumer safety.” Separately, the House Appropriations Committee recently approved a spending bill and an attached report that expresses concerns about health risks from cannabis-derived products, while also encouraging research into the therapeutic benefits of psychedelics. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — Meanwhile in Congress, the House last month approved amendment to let military veterans receive recommendations for medical marijuana through their doctors at the Department of Veterans Affairs (VA) The full House also recently passed a Farm Bill with provisions aimed at aiding industrial hemp producers—but without any language to delay or alter the federal recriminalization of hemp THC products that’s scheduled to take effect later this year. The post Congressional Committee Votes To Block Medical Marijuana From Being Covered Under Workers’ Comp For Federal Employees appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Most genuine & authentic Escort service in Chandigarh where you get the best mind boggling orgasm 24/7 unlimited fun.

The White House is making it clear that President Donald Trump wants Congress to take action to amend a law that threatens to federally recriminalize hemp-derived full-spectrum CBD products in November. The administration “welcomes the opportunity to work with the Congress to, at a minimum, update the statutory definition of final hemp-derived cannabinoid products to allow Americans to benefit from access to appropriate full-spectrum CBD products,” the Office of Management and Budget (OMB) said on Thursday, “while preserving the Congress’s intent to restrict the sale of products that pose serious health risks.” The call to avert a broad prohibition on hemp CBD products was included in a statement of administration policy about an annual agriculture spending bill that passed the House of Representatives the same day. Several lawmakers had filed amendments to that legislation to keep hemp products legal, but each was either blocked by the House Rules Committee from advancing to a floor vote or withdrawn by its sponsor. “The Administration supports advancement of this legislation, but looks forward to addressing its concerns prior to enactment,” OMB said in its statement of administration policy. “The Administration looks forward to working with the Congress to provide more input as the bill’s legislative process unfolds.” The Senate Appropriations Committee was set to take up its version of the Fiscal Year 2027 agriculture spending bill on Thursday, but that meeting was cancelled amid disagreements on unrelated issues. Hemp derivatives with less than 0.3 percent delta-9 THC on a dry-weight basis were federally legalized under the 2018 Farm Bill that Trump signed during his first term in office. But late last year, he signed new legislation containing provisions that will redefine hemp to make it so only products with 0.4 milligrams of total THC per container will remain legal after November 12. In April, the president himself urged congressional lawmakers to again redefine hemp to avoid recriminalization of full-spectrum CBD products. “I am calling on Congress to update the Law to ensure that Americans can continue to access the full-spectrum CBD products they have come to rely on, and that help them, while preserving Congress’s intent to restrict the sale of products that pose Health risks,” Trump said in a Truth Social post on the same day his administration announced it is moving forward with rescheduling marijuana. “We must get this done RIGHT and FAST, especially for those who saw that CBD helps them,” he said. “Plus, I am told it will also help our GREAT FARMERS, who we love, and will always be there for.” Industry advocates say that the law as enacted last year not only threatens to prohibit intoxicating and synthetic cannabinoid products but also stands to remove popular full-spectrum CBD products that many Americans use therapeutically from the market. “ONE in FIVE adults used it in the past year, and many say it improved their chronic pain enormously,” the president said in his social media post, adding that hemp-derived CBD “has made a HUGE difference for so many people.” He also referenced a new initiative the administration launched in April to cover up to $500 worth of hemp-derived products each year for eligible Medicare patients. The program being implemented by the Centers for Medicare & Medicaid Services (CMS) focuses largely on CBD but also allows products to have up to 3 milligrams of total THC per serving. “In December, I signed a very important Executive Order calling for Research and Innovation for Hemp-derived CBD,” Trump said. “Our wonderful Dr. Mehmet Oz moved fast to follow the directive in the Executive Order, and launched a model for some Seniors earlier this month. But more must be done!” “Please get it done, and SOON,” the president said in reference to a congressional fix for the broad recriminalization set to take effect in November. “Thank you for your attention to this matter!” It’s not clear how far Trump wants to scale back the scope of the scheduled federal restrictions on hemp products and what kinds of revised THC rules and limitations he would prefer to sign into law. Separately, White House officials recently provided a congressman’s office with feedback on hemp regulatory legislation. In April, Vince Haley, director of the White House Domestic Policy Council and James Braid, assistant to the president for legislative affairs, sent hemp policy suggestions to Rep. Andy Barr (R-KY). “We appreciate your work to advance the policy of” an executive order Trump signed in December that included provisions seeking to protect Americans’ access to CBD products, the staffers wrote in a letter to the congressman. “We are transmitting for your consideration draft legislative text and comments to address the statutory definition of final hemp-derived cannabinoid products in order to allow Americans to benefit from access to appropriate full-spectrum CBD products while preserving the Congress’s intent to restrict the sale of products that pose serious health risks,” the White House officials said, according to a social media post containing a screenshot of the letter. “We are available for discussion and further technical assistance.” Separately, anti-marijuana organizations filed a lawsuit suit against the Medicare hemp CBD coverage policy—but a judge dismissed the case last month, ruling that they don’t have standing. Lawyers for Health and Human Services Sec. Robert F. Kennedy Jr. and CMS Director Mehmet Oz had filed a brief asking that the case be dismissed. The White House Office of Management and Budget has also held a series of meetings about a Food and Drug Administration (FDA) CBD products enforcement policy. FDA issued guidance making clear that it does not intend to interfere with implementation of the Medicare hemp-derived products coverage plan. CMS separately finalized a rule that will allow coverage of some hemp products as specialized, non-primarily health-related benefits through Medicare Advantage plans. As hemp products have become more popular with consumers, some large brands are attempting to get in on action. Major retailer Target, for example, is expanding its participation in the hemp-derived THC beverage market. Last year, the company began a pilot program involving sales of cannabis drinks at 10 select stores in Minnesota. That apparently went well, and now the company has obtained licenses from Minnesota regulators to sell lower-potency hemp edible products—including THC drinks—at all 72 of its stores in the state. A U.S. Department of Agriculture report published in April shows that farmers in the U.S. grew three-quarters of a billion dollars worth of hemp crops in 2025—a 64 percent increase from the prior year. The post White House Pushes Congress To Keep Hemp CBD Products Legal By Amending Broad Ban That’s Set To Take Effect Later This Year appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Congressional panel: Keep testing truckers for marijuana; GOP lawmakers “troubled” over 280E tax relief; LA medical cannabis bill; AL sales start Subscribe to receive Marijuana Moment’s newsletter in your inbox every weekday morning. It’s the best way to make sure you know which cannabis stories are shaping the day. Get our daily newsletter. Email address: Leave this field empty if you're human: Your support makes Marijuana Moment possible… Free to read (but not free to produce)! We’re proud of our newsletter and the reporting we publish at Marijuana Moment, and we’re happy to provide it for free. But it takes a lot of work and resources to make this happen. If you value Marijuana Moment, invest in our success on Patreon so we can expand our coverage and more readers can benefit: https://www.patreon.com/marijuanamoment / TOP THINGS TO KNOW The House Appropriations Committee approved a funding bill and report that directs federal officials to continue drug testing truck drivers, airline pilots and other safety-sensitive workers for marijuana—regardless of the Trump administration’s cannabis rescheduling move. Sen. James Lankford (R-OK) and House Budget Committee Chairman Jodey Arrington (R-TX) sent a letter telling Treasury Secretary Scott Bessent they are “troubled” that marijuana businesses will be eligible for tax relief under rescheduling and pressing him for answers on how removal of the 280E penalty will apply. Louisiana Gov. Jeff Landry (R) allowed a bill to let patients with terminal and irreversible conditions use medical cannabis in hospitals to take effect without his signature. Connecticut Gov. Ned Lamont (D) signed a bill to expand a psychedelic pilot program to let all adults who meet eligibility criteria participate—instead of just veterans, retired first responders and healthcare workers—in anticipation of federal approval of psilocybin or MDMA. The Women’s National Basketball Association and WNBA Players Association approved a new collective bargaining agreement that removes marijuana from the banned substances list and sets out rules for how players can invest in and promote cannabis companies. Alabama medical cannabis sales have finally launched, five years after lawmakers passed legalization legislation. / FEDERAL The U.S. Court of Appeals for the Eighth Circuit ruled that rap lyrics and a music video can be admitted as evidence in a drug trafficking case. Nebraska independent Senate candidate Don Osborn tweeted that Sen. Pete Ricketts (R-NE) “is doing everything he can to DENY Nebraskans access to medical marijuana… He’s preventing cancer patients and kids with seizure disorders from getting the medicine they desperately need. Meanwhile, the Ricketts family owns the Chicago Cubs, the first MLB team to sell hemp-derived drinks at Wrigley Field. To Pete Ricketts, marijuana is good if his family can profit off it. Bad if it can benefit Nebraskans.” / STATES South Carolina Democratic gubernatorial candidates discussed their support for marijuana reform during a debate. Oklahoma Republican gubernatorial candidate Mike Mazzei said he wants to crack down on illegal marijuana growing operations but does “not support wiping out Oklahoma-based businesses who want to properly provide some product” through the medical cannabis program. The New York Senate confirmed Gov. Kathy Hochul’s (D) nominee to lead the Office of Cannabis Management. Washington State regulators approved changes to marijuana advertising rules. Michigan regulators filed a complaint against a marijuana business over alleged violations. South Dakota regulators published updated states on patients participating in the medical cannabis program. Minnesota regulators sent a newsletter with updates on various cannabis issues. / LOCAL Denver, Colorado officials published an updated list of neighborhoods with an “undue” concentration of marijuana businesses. / INTERNATIONAL New South Wales, Australia’s government is proposing legislation to protect medical cannabis patients from driving under the influence charges. / SCIENCE & HEALTH A study found that “combining THC and CBD with cisplatin results in enhanced and mechanistically diverse anticancer effects, with a higher degree of selectivity for cervical cancer cells compared to non-cancerous MCF-12A cells by inducing apoptosis and autophagy while inhibiting DNA repair capacity.” A study found that “in New York State, geographic inaccessibility of medical dispensaries and the high costs of certification and cannabis products are central barriers to medical cannabis program participation.” / ADVOCACY, OPINION & ANALYSIS The National Compassionate Care Council formed a medical advisory board. / BUSINESS Trulieve Cannabis Corp. is moving to segregate its “mixed-use cannabis business from its medical cannabis business in order to apply to list” on the New York Stock Exchange. Village Farms International, Inc. shareholders elected board of directors members. Make sure to subscribe to get Marijuana Moment’s daily dispatch in your inbox. Get our daily newsletter. Email address: Leave this field empty if you're human: Photo courtesy of Mike Latimer. The post WNBA takes cannabis off banned list & sets player endorsement rules (Newsletter: June 5, 2026) appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Awesome things you've generally imparted to us. Simply continue written work this sort of posts.The time which was squandered in going for educational cost now it can be utilized for studies.Thanks marble dining table

Aria Telco Management offers a versatile VOIP phone system for businesses in Perth, ideal for small business needs. Their services include installation and management of business phone systems and NBN plans. Features include conference calling, call recording, and easy integration with stable internet connections. They also offer number porting for existing business phone numbers, ensuring a smooth transition and uninterrupted connectivity

Connecticut’s governor has signed a bill to expand a pilot program that’s meant to explore the therapeutic potential of psychedelics such as psilocybin and MDMA. The legislation sponsored by the Joint Committee on Public Health cleared the House of Representatives in 122-27 vote last month after passing the Senate by a unanimous 35-0 vote in April. Gov. Ned Lamont (D) signed it into law on Thursday. The new law builds upon an existing psychedelic-assisted therapy program involving military veterans and first responders who elect to participate in clinical trials. It also repeals and replaces the current statute to make it so any adults 18 or older who meet clinical eligibility criteria established by the institutional review board of the medical school selected to administer the pilot program could be eligible to receive psychedelics treatment in a clinical setting, with researchers tasked with studying the efficacy of the novel therapeutics. It additionally removes existing language stipulating that the pilot program must end upon federal approval of psilocybin or MDMA by the Drug Enforcement Administration (DEA) or a successor agency. Finally, it strikes outdated language requiring the state Department of Mental Health and Addiction Services to create and facilitate the program by January 2023. Rep. Cristin McCarthy Vahey (D) said ahead of the House vote that the legislation is “critically important,” citing recent moves by federal officials to expedite research on and therapeutic access to psychedelics after President Donald Trump signed an executive order on the issue in April. “If the fast track is successful and these drugs are approved, our study will end, making us effectively unable both to continue the study and losing the benefit of the investment we’ve already made as a state—but in addition making us ineligible for those federal matching funds,” she said on the floor ahead of the most recent vote. Under the Connecticut bill, SB 191, the officials would be mandated to “establish, within available appropriations, a psychedelic-assisted therapy pilot program, to be administered by a medical school in the state.” That program “shall provide qualified patients with MDMA-assisted or psilocybin-assisted therapy as part of a research program approved by the federal Food and Drug Administration,” or FDA, it says. Rep. Nicole Klarides-Ditria (R) also spoke in support of the legislation, saying “this expanded access is for innovative research. It’s evidence-based research. Mental health and the treatment is critical for the state of Connecticut.” “Expanding it to anybody 18 and older is truly going to help us continue with this pilot program,” she said. To that point, McCarthy Vahey said that under the current structure’s restrictions there has been difficulty recruiting enough participants. “The current pilot is narrowly focused and tailored. And in fact, it will remain the priority to have veterans, first responders and our direct health care workers be the focus of the study,” she said. “But we are being told that some of the folks are having a little difficulty with recruiting. The goal is to get to a cohort of 50, and so this will give them a little bit of leeway to do so.” Rep. Dave Yaccarino (R) noted that he voted against the original psychedelics program legislation a few years ago but said he has since learned about studies showing benefits for “men and women that come in from combat, our firefighters, our police that see tragic events.” “If this helps, and it’s controlled, I think you have to support it,” he said. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — Meanwhile, last year, the Connecticut House of Representatives approved a bill to decriminalize psilocybin for adults—despite questions about whether the governor would support it after he rejected an earlier version of the reform measure. That marked the third session in a row that Connecticut lawmakers worked to advance psilocybin decriminalization. In 2023, the reform measure cleared the House but did not move through the Senate. The Judiciary Committee also approved a version in 2024. Lamont also signed a large-scale budget bill in 2022 that included provisions to set the state up to provide certain patients with access to psychedelic-assisted treatment using substances like MDMA and psilocybin. Lawmakers also sent the governor legislation this session to address cannabis product THC potency limits. Separately, legislation to allow medical marijuana use by certain qualifying patients at health facilities such as hospitals, nursing homes and hospices received a committee hearing but did not advance. Photo courtesy of Mark Groeneveld. The post Connecticut Governor Signs Bill To Expand Psychedelics Pilot Program In Preparation For Federal FDA Approval appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

The WNBA has officially removed marijuana from its prohibited substances list while also laying out rules for how players can invest in and promote cannabis companies. At the same time, however, the women’s basketball league is also adding several psychedelics to the list of banned drugs. As part of negotiations between the Women’s National Basketball Players Association and WNBA earlier this year, the league offered to remove cannabis from its drug testing protocol. Now, under the terms of the long-form version of a new Collective Bargaining Agreement (CBA) signed by representatives of both sides, marijuana no longer appears on the prohibited substances list, whereas under the prior CBA it was included under “Drugs of Abuse.” Prior WNBA policy treated cannabis significantly more restrictively compared to the NBA, as well as multiple other professional sports leagues beyond basketball that have also adopted reforms amid the state legalization movement. First-time offenses generally resulted in treatment referrals, but repeated violations could lead to fines and suspensions. Under the new rules, players could still be subject to testing for cannabis if they enter the league’s Drugs of Abuse Program, if they are found to have been under the influence “while engaged in activities” for the team or the league or if they have “a dependency or other related issue involving the use of marijuana.” Those who are referred to a marijuana treatment program and do not comply with the rules would be subject to fines of $300 per day. Any player who exhibits a “pattern of behavior that demonstrates a mindful disregard for her treatment responsibilities” or tests positive for marijuana would face escalating penalties such as a $3,000 fine or suspension for three or more games. Players could be subject to “reasonable cause” drug testing or administrative proceedings if they are convicted of a felony involving the distribution or marijuana. At the same time WNBA and the players union are loosening up on marijuana, however, it has also added specific entries for the psychedelics dimethyltryptamine (DMT), ibogaine, psilocybin and psilocin to the prohibited substances list for the first time. Also prohibited under the new policy are synthetic cannabinoids, which the document describes as “including, but not limited to, Delta-8 tetrahydrocannabinol (also called delta-8-THC)) and their By-Products.” Separately, the CBA also addresses players’ investment in and promotion of companies that sell marijuana and hemp-derived CBD products. It says that players can hold a direct or indirect ownership interest in marijuana companies as long as the interest is passive (meaning no management, governance, voting, or executive role or other operational rights or roles” and they have less than a 50 percent stake in the business. There is also a requirement for the company to operate “in compliance with all applicable laws and regulations,” and the document specifically notes that players may not hold any ownership interest in a business “that produces or sells any products containing any Prohibited Substance or any other Schedule I or II substance under the Controlled Substances Act.” The WNBA and WNBPA have announced the following statement pic.twitter.com/ne9m4Zg7Mo — WNBA (@WNBA) May 22, 2026 While marijuana has been classified under Schedule I of the Controlled Substances Act since 1970, the Trump administration in April announced that it was moving state-licensed medical cannabis, as well as any cannabinoid products approved by the Food and Drug Administration, to Schedule III, where WNBA’s prohibition would presumably no longer apply. Broader reclassification of marijuana to Schedule III will be the topic of a hearing scheduled to begin later this month. WNBA’s rules for CBD-specific companies are looser than those for marijuana businesses in that they don’t require passive interest or less than 50 percent ownership. The document also says that players can actively promote and endorse that sell CBD products. If the products are produced by a marijuana company, however, players will first need to receive permission from the league and the union. “Without limiting such approval right of the WNBA and the Players Association, the promotion or endorsement by a player of a CBD Product that is produced or sold by a Marijuana Company (A) will not be permitted if such CBD Product is associated by the Marijuana Company with any Marijuana Product (e.g., the CBD Product is marketed or sold under a brand that also includes or refers to Marijuana Products) or if any proposed promotion creates a reasonable risk of public confusion with any Marijuana Product, and (B) if approved, shall be subject to any terms and conditions imposed by the WNBA and/or the Players Association.” “For clarity, any investments in or promotions or endorsements of entities that produce or sell products containing a form of cannabis (including, for clarity, a CBD form of cannabis) not expressly permitted…are prohibited,” the agreement that was finalized on May 22 says. “In the event a player engages in a prohibited investment, promotion, or endorsement, then, without limiting other WNBA rights or remedies, the player shall be required to promptly dispose of her ownership interest in the prohibited investment and/or immediately terminate her participation in the prohibited promotion or endorsement, as applicable.” The league gave some indication about its willingness to accept the changing tides around cannabis in 2024, when the WNBA team New York Liberty entered into a partnership with a CBD beverage company. Meanwhile, Brittney Griner—a WNBA player who was previously incarcerated in Russia over possession of marijuana—pulled out of an appearance at a cannabis event last year after discovering what she felt was a threatening message in her hotel room. Conference attendees had hoped to hear from Griner about the nature of her incarceration in Russia, which helped fuel international debate about cannabis prohibition laws domestically and abroad. How other sports leagues have navigated marijuana policy for players amid the reform movement. NBA, for its part, removed marijuana from the banned substances list for players in 2023, and it also freed them up to invest in and promote cannabis companies. The NFL, meanwhile, reached an agreement with its players union in 2024 to further reform its marijuana policies, significantly reducing fines for positive tests while increasing the allowable THC threshold for players. About four years after NFL ended the practice of suspending players over cannabis or other drugs as part of a collective bargaining agreement, the league again revised its Substances of Abuse Policy and Performance Enhancing Substances Policy. The National Collegiate Athletic Association (NCAA) in 2024 voted to remove marijuana from its banned substances list for Division I players. The reform builds on a 2022 change that increased the allowable THC threshold for college athletes, aligning NCAA’s rules with those of the World Anti-Doping Agency (WADA). In 2024, Nevada regulators officially adopted a rule change that will protect athletes from being penalized for using or possessing marijuana in compliance with state law. The head of the U.S. Anti-Doping Agency (USADA) blasted the “unfair” ban on marijuana for athletes competing in international sport events, including the Olympics that were underway in Paris at the time of the comments. USADA CEO Travis Tygart said it was “disappointing” that WADA has maintained the cannabis prohibition based on what he considers a misguided justification. WADA did carry out a review into its marijuana policy at the request of USADA and the White House Office of National Drug Control Policy (ONDCP) following the controversial suspension of U.S. runner Sha’Carri Richardson, who was barred from participating in the Olympics in 2021 after she tested positive for THC. Richardson said she used cannabis to cope with the recent passing of her mother. While UFC announced in late 2023 that it was formally removing marijuana from its modified banned substances list for athletes, the league notified participants that the reform didn’t apply under California State Athletic Commission (CSAC) rules. UFC advised fighters that they could be subject to a $100 fine by CSAS if they tested over 150 nanograms of THC per milliliter ahead of the UFC 298 event that took place in February. In 2024, NFL announced it was partnering with Canadian researchers on a clinical trial to test the safety and efficacy of CBD for pain management and neuroprotection from concussions—key issues for many football players who experience injuries as part of the game. The post WNBA Removes Marijuana From Banned Substances List And Sets Rules For Player Endorsements Of Hemp CBD Products appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

A congressional committee is directing federal officials to continue requiring government employees and safety-sensitive workers such as truck drivers and airline pilots to be drug tested for marijuana, “regardless of any future changes to the legal status or scheduling.” The panel is separately urging agencies to focus on determining whether “commercially feasible technology” is available to help law enforcement detect cannabis-impaired driving, and is also supporting efforts to develop an “objective standard” to measure recent marijuana use. The House Appropriations Committee on Wednesday approved the Fiscal Year 2027 Transportation, Housing and Urban Development, and Related Agencies spending bill and an attached report that includes several cannabis-related provisions. One section, added during the markup via an amendment, notes that members are “aware of ongoing changes to Federal and State laws governing the legal status and scheduling of certain controlled substances” such as marijuana, and says that those reforms “should not be construed to alter existing Federal drug testing requirements applicable to Federal employees and individuals serving in safety-sensitive positions.” Workers in positions regulated by the Department of Transportation (DOT) should continue to be tested for cannabis and other drugs, “regardless of any future changes to the legal status or scheduling of such substances under Federal law,” it says. “Drug testing.—The Committee is aware of ongoing changes to Federal and State laws governing the legal status and scheduling of certain controlled substances. The Committee emphasizes that such changes should not be construed to alter existing Federal drug testing requirements applicable to Federal employees and individuals serving in safety-sensitive positions. The Committee directs DOT to continue requiring testing for marijuana, cocaine, opioids, amphetamines, phencyclidine (PCP), and any additional controlled substances included on the Federal drug testing panel for individuals occupying safety-sensitive positions regulated by the Federal Aviation Administration, Federal Motor Carrier Safety Administration, Federal Railroad Administration, Federal Transit Administration, and Pipeline and Hazardous Materials Safety Administration, regardless of any future changes to the legal status or scheduling of such substances under Federal law.” Last month, a pair of Republican lawmakers teamed up with anti-marijuana groups to push for a “carve-out” to ensure that safety-sensitive workers continue to be tested and punished for cannabis use. Days earlier, DOT had issued new guidance saying that truck drivers, airline pilots and other safety-sensitive workers still cannot use medical marijuana without punishment despite the Trump administration’s move to reschedule it. “Marijuana use is not compatible with safety-sensitive functions,” the agency said. Medical review officers (MROs) who receive drug test results indicating cannabis consumption cannot deem them to be negative for illegal substance use, even when an employee says it was the result of state-licensed medical marijuana, the department said. “Currently, there is no instance when the MRO could verify a laboratory-confirmed marijuana positive drug test result as ‘negative’ when an employee claims the positive was caused by a State licensed marijuana product,” DOT said, explaining that even after rescheduling, medical marijuana dispensed in accordance with state law “does not constitute” a drug that has been approved by the Food and Drug Administration (FDA). Adopted by voice vote. — House Appropriations Amendments (@AppropsAmendmts) June 4, 2026 While it is widely accepted that safety-sensitive transportation workers should not perform their jobs under the influence of marijuana or other substances, legalization supporters point out that cannabis metabolites can stay in a person’s system for weeks after use and still be detected on drug tests even when there is no impairment. The new report approved by the congressional committee also contains a passage saying that “as more jurisdictions legalize the use of recreational cannabis, law enforcement officers will need additional reliable tools to protect drivers and other road users.” It calls on the National Highway Traffic Safety Administration (NHTSA) to “assess currently available and potentially commercially feasible technology that could be used by highway enforcement authorities to assess cannabis presence.” “Cannabis-related impairment and technology.—The Committee recognizes that as more jurisdictions legalize the use of recreational cannabis, law enforcement officers will need additional reliable tools to protect drivers and other road users. The Committee directs NHTSA, in coordination with other relevant Federal agencies, to assess currently available and potentially commercially feasible technology that could be used by highway enforcement authorities to assess cannabis presence. The Committee directs NHTSA to provide a preliminary briefing on the plans for this assessment within 180 days of enactment of this Act. The Committee simultaneously supports the development of an objective standard to measure marijuana to identify recent cannabis use and/or a related field test to ensure highway safety.” Separately, the report addresses the issue of impaired driving more generally by urging NHTSA consider creating an interagency Impaired Driving Task Force and brief lawmakers on “any cross-agency initiatives to reduce the number of crashes and deaths associated with impaired driving.” “Interagency impaired-driving task force.—The Committee is concerned with the rising number of crashes associated with drivers operating their motor vehicles while impaired. The Committee notes the existence of the Federal Drug-Impaired Driving Working Group and urges NHTSA to consider the merits of creating an interagency Impaired Driving Task Force or other partnerships to increase cross-agency collaboration among Federal, State, and local levels to prevent and respond to impaired driving. The Committee directs NHTSA to brief the Committees on Appropriations regarding any cross-agency initiatives to reduce the number of crashes and deaths associated with impaired driving that are identified as a result of this collaboration.” Last month, a separate congressional committee approved transportation legislation containing provisions to require federal officials to study the issue of driving of driving under the influence of marijuana and other drugs and propose “evidence-based impairment standards.” The new funding bill itself that was approved by the Appropriations Committee in a 34-27 vote this week contains a provision blocking the NHTSA from using any of its appropriated monies to “encourage illegal drug or alcohol use” in its public service announcement advertising campaigns. “SEC. 141. None of the funds provided in this Act may be used to encourage illegal drug or alcohol use in the National Highway Traffic Safety Administration’s impaired driving advertising campaigns.” The rider is seemingly in response to previous marketing materials that leaned into cannabis culture to deter impaired driving. Marijuana legalization opponents cheered when a similar provision was approved last year. Federal officials launched a public service announcement effort to discourage impaired driving around the cannabis holiday 4/20 this year. NHTSA recently partnered with the Ad Council on a separate campaign to “challenge the dangerous belief that it’s safe to drive after consuming marijuana,” with a disturbing ad that they said depicts a real-life story of a child killed by a driver who was under the influence of cannabis. That campaign represented a departure from recent cannabis-related NHTSA ads, which have taken a less “Just Say No” approach to marijuana use risk messaging and, at times, leaned into to cannabis culture to promote education around the potential consequences of driving while high. What stood out about the messages and graphics was the lack of fear-mongering and negative depictions of cannabis consumers that’s long been a hallmark of federal marijuana PSAs, such as those funded by the White House Office of National Drug Control Policy (ONDCP) in the 1990s and 2000s that perpetuated stigmas about laziness or forgetfulness. Instead, NHTSA seemed to be leveraging cannabis culture, with warnings against impaired driving that are coupled with images meant to appeal to marijuana consumers. Last October, Transportation Secretary Sean Duffy suggested President Donald Trump was “getting pressure” to reschedule cannabis—arguing that marijuana is “really addictive” and saying that policy reform around the issue sends a “dangerous” message. “At a time when culture is pushing and celebrating the use of marijuana, we’re not talking about the risk,” Duffy said. NHTSA Administrator Jonathan Morrison said last year that he was prepared to “double down” on increasing awareness about the risk of marijuana-impaired driving in partnership with the White House. In 2021, meanwhile, NHTSA tried to get the word out about the dangers of impaired driving through an ad featuring a computer-generated cheetah smoking a joint and driving a convertible. Critics noted that the world’s fastest land animal hardly fits the stereotype of a cannabis consumer that the government has historically played into, while other commenters pointed out at the time that the ad made the cheetah look confusingly cool as he broke the law. The agency also played on horror-movie tropes in a 2020 ad featuring two men running for their lives from an axe murderer. The pair ultimately find a vehicle to escape the scene, but the driver pauses before he turns the key in the ignition. “Wait wait wait,” he says. “I can’t drive. I’m high.” While it’s widely understood that driving under the influence of cannabis can be dangerous, the relationship between consumption and impairment is a messy one. In 2024, for example, a scientific review of available evidence on the relationship between cannabis and driving found that most research “reported no significant linear correlations between blood THC and measures of driving,” although there was an observed relationship between levels of the cannabinoid and reduced performance in some more complex driving situations. “The consensus is that there is no linear relationship of blood THC to driving,” the paper concluded. “This is surprising given that blood THC is used to detect cannabis-impaired driving.” Meanwhile, the Department of Justice recently announced a new breakthrough in the development of a marijuana breathalyzer, with a study partly funded by the federal government showing a potential pathway for a “portable, low cost” device that looks like an inhaler for asthma, built with 3-D printed material that can detect delta-9 THC without secondary lab analysis. Federal agencies outside of DOJ have also recognized the need for the THC detection technology. For example, last year the National Institute of Standards and Technology (NIST) under the U.S. Department of Commerce planned a workshop aimed at facilitating “an open and candid discussion” about the development and implementation of device to test a person’s breath for marijuana impairment. In 2023, a federally funded report by researchers at NIST and the University of Colorado Boulder concluded that evidence does “not support the idea that detecting THC in breath as a single measurement could reliably indicate recent cannabis use.” A DOJ researcher in 2024, meanwhile, cast doubt on whether a person’s THC levels are even a reliable indicator of impairment, saying states may need to “get away from that idea.” That issue was also examined in a federally funded study in 2024 that identified two different methods of more accurately testing for recent THC use that accounts for the fact that metabolites of the cannabinoid can stay present in a person’s system for weeks or months after consumption. Also that year, researchers behind a federally funded study said they’d developed new procedures to enhance the selectivity of a popular forensic testing method, allowing better detection of delta-9 THC and its metabolites in blood. A study published in 2019 concluded that those who drive at the legal THC limit—which is typically between two to five nanograms of THC per milliliter of blood—were not statistically more likely to be involved in an accident compared to people who haven’t used marijuana. Separately, the Congressional Research Service (CRS) in 2019 determined that while “marijuana consumption can affect a person’s response times and motor performance … studies of the impact of marijuana consumption on a driver’s risk of being involved in a crash have produced conflicting results, with some studies finding little or no increased risk of a crash from marijuana usage.” In a report in 2024, NHTSA said there’s “relatively little research” backing the idea that THC concentration in the blood can be used to determine impairment, again calling into question laws in several states that set “per se” limits for cannabinoid metabolites. “Several states have determined legal per se definitions of cannabis impairment, but relatively little research supports their relationship to crash risk,” that report said. “Unlike the research consensus that establishes a clear correlation between [blood alcohol content] and crash risk, drug concentration in blood does not correlate to driving impairment.” The post Congressional Committee Directs Feds To Keep Testing Truck Drivers For Marijuana, Regardless Of Trump’s Rescheduling Move appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Thanks for a very interesting blog. What else may I get that kind of info written in such a perfect approach? I’ve a undertaking that I am simply now operating on, and I have been at the look out for such info. เว็บแทงบอล

I recently came across your blog and have been reading along. I thought I would leave my first comment. I don't know what to say except that I have enjoyed reading. Nice blog. I will keep visiting this blog very often. แทงบอลสเต็ป

A newly enacted Louisiana law will let patients with terminal and irreversible conditions use medical marijuana in hospitals. Gov. Jeff Landry (R) allowed the reform to be enacted without his signature on Monday, rather than signing or vetoing it. The House of Representatives had approved the legislation from Sen. Katrina Jackson-Andrews (D) in a 54-44 vote last month after it previously passed the Senate by a margin of 33-2 in April. Under the proposal, hospitals will have to create written guidelines allowing covered patients to consume medical cannabis on-site in forms other than smoking or vaping. Under an amendment adopted by a Senate committee last month, emergency or outpatient departments are exempted from the policy. The revised legislation also clarifies that patients and primary caregivers are responsible for acquiring and administering medical marijuana, which must be “stored securely at all times in a locked container provided by the patient.” Health care professionals and staff are prohibited from “administering, storing, retrieving, or assisting the patient with the medical marijuana,” the text says. The amendment, which the sponsor worked on with help from the Louisiana Hospital Association, also allows hospitals to opt out of the policy if federal officials take action against any healthcare facility in the state over medical cannabis use, rather than only allowing those that were specifically targeted to stop complying. “This bill was brought at the request of constituents who believe that therapeutic medical marijuana, which is already legal in this state, should be offered in hospitals when patients are terminally ill or otherwise in need the comfort of this medicine,” Jackson-Andrews told the Senate Health and Welfare Committee when the panel took up the legislation. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — Meanwhile in Louisiana, another piece of drug policy legislation that is before the governor for action would create a psychedelic-assisted therapy pilot program, using opioid settlement dollars to fund clinical trials aimed at developing alternative treatments such as psilocybin, ibogaine and MDMA. At the same time, however, advocates are alarmed that Landry recently signed legislation that threatens to send people to jail for up to one year if they smoke marijuana within 2,000 feet of a school property—including a college campus. The governor said in a video posted to social media that he is “tired” of smelling cannabis at football games. Separately, a lawmaker recently filed a proposal that would create a new state task force to “study and develop findings and recommendations regarding the potential legalization of recreational marijuana”—though it did not advance. Another Louisiana legislator, meanwhile, recently introduced a bill to create an adult-use marijuana legalization pilot program in the state to determine whether the reform should eventually be expanded and permanently codified. Rep. Candace Newell (D)—who has long championed legislation to end cannabis criminalization and filed a similar legal marijuana pilot program measure last session—is sponsoring what’s titled the “Adult-Use Cannabis Pilot Program Regulation and Enforcement Act.” Newell’s earlier version of the pilot program legislation didn’t advance to enactment last year, and lawmakers that session also rejected other marijuana reform proposals such as one that would have established a tax system to prepare the eventual legalization of adult-use cannabis. Meanwhile in Louisiana, Attorney General Liz Murrill (R) recently joined and then days later withdrew from a lawsuit challenging the Trump administration’s federal marijuana rescheduling move. Photo courtesy of Brian Shamblen. The post Louisiana Will Let Terminally Ill Patients Use Medical Marijuana In Hospitals After Governor Allows Bill To Take Effect Without His Signature appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Thanks for taking the time to discuss this, I feel strongly about it and love learning more on this topic. If possible, as you gain expertise, would you mind updating your blog with extra information? It is extremely helpful for me. แทงบอลสเต็ป

I wanted to thank you for this excellent read!! I definitely loved every little bit of it. I have you bookmarked your site to check out the new stuff you post. เว็บแทงบอล

Thanks for the blog loaded with so many information. Stopping by your blog helped me to get what I was looking for. แทงบอล

“I will be able to remove some very dangerous pharmaceuticals, and I’ll be able to replace them with something that God put on this earth.” By Anna Barrett, Alabama Reflector Amanda Taylor, a patient advocate, bought the first medical cannabis product in Alabama Wednesday morning at Callie’s Apothecary in Montgomery. Taylor, who has multiple sclerosis, said she has advocated for the natural medicine in her home state for about 11 years. She moved to Arizona for access to medical cannabis and to work in the industry, but came home to be a “voice for the patients.” “I’ve always said it’s not all about me, it’s about the patients. If it was about me, I would have stayed in Arizona, but this is about a better quality of life, not getting high, but about a better quality of life,” she said. The Alabama medical cannabis law, enacted in 2021, allows registered physicians to recommend cannabis for about 15 medical conditions, including cancer, depression, Parkinson’s Disease, PTSD, sickle-cell anemia, chronic pain and terminal diseases. The approved product forms are restricted to tablets, tinctures, patches, oils and gel cubes (only peach flavor), with raw plant material and smokable forms remaining prohibited. Taylor purchased a water-soluble tincture and peach-flavored gel cubes. She said she hopes the products will last her about a month and resolve her nausea, vomiting and tremor symptoms of multiple sclerosis. She has 45 legions on her brain and one on her spine. “I will be able to remove some very dangerous pharmaceuticals, and I’ll be able to replace them with something that God put on this earth for this specific reason,” she said. Taylor drove over two hours from Cullman, Alabama, to get to Callie’s Apothecary, the first medical cannabis dispensary to open in the state. When the program is fully up and running, there will be 12 dispensaries across the state between four companies. Three of the companies, CCS of Alabama, LLC, GP6 Wellness, LLC and RJK Holdings, LLC, have licenses and are expected to open their storefronts this summer, according to Alabama Medical Cannabis Commission (AMCC) Director John McMillan. A fourth license is pending litigation, but is likely to go to Yellowhammer Medical Dispensaries, LLC. People who suffer from the qualifying conditions must get approval from their physician and enter the patient registry in order to buy products at a dispensary. Litigation has also held up access to medical cannabis. Some firms sued the commission for not being awarded a license, citing a discriminatory process. Another case involved five parents that sued the commission over delays in access to cannabis, which was dismissed in August. McMillan said Wednesday there are over 300 patients on the registry. As of Wednesday, there are 52 physicians certified to recommend medical cannabis to patients in Alabama, according to the Alabama Board of Medical Examiners, but there will likely be more now that patients can get products. “It’s all about the patients, every step of the whole process, and so I think wisely they’ve sort of held off until they know that the patient can get a recommendation and then get a product,” McMillan said. Taylor said she hopes that the stigma around cannabis as medicine will go away as the industry changes in Alabama. “I see this growing exponentially, because once people see the results and see the difference that it makes, and that it’s not about getting high and how you can function and be a productive member of society,” she said. “There’s no shame in that. This is medicine.” This story was first published by Alabama Reflector. The post Alabama Medical Marijuana Sales Finally Launch, Years After Lawmakers Passed Legalization appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

A pair of Republican lawmakers sent a letter to the Trump administration’s treasury secretary on Wednesday saying they are “concerned” and “troubled” that marijuana businesses will be eligible for tax relief now that cannabis is being partially rescheduled under federal law. Moving marijuana from Schedule I of the Controlled Substances Act (CSA) to Schedule III will have “significant implications for the federal tax treatment of marijuana businesses,” Sen. James Lankford (R-OK) and Rep. Jodey Arrington (R-TX), who chairs the House Budget Committee, wrote in a letter to Treasury Secretary Scott Bessent. That’s because an Internal Revenue Service code known as 280E, which has prevented them from taking ordinary tax deductions and credits that are available to most businesses, only applies to Schedule I and II substances. “We have long been concerned about the potential fiscal and societal consequences of rescheduling,” the GOP lawmakers said, citing legislation that previously introduced called the No Deductions for Marijuana Businesses Act that would continue to prevent the cannabis industry from escaping the 280E penalty even under rescheduling. Under an order issued by Acting Attorney General Todd Blanche last month, marijuana regulated by a state medical cannabis license immediately moved to Schedule III. Marijuana products such as those in state-legal recreational markets remain in Schedule I for now, however, subject to a hearing process set to begin next month to consider broader rescheduling of cannabis. Lankford and Arrington said in the letter to the treasury secretary that they are “particularly troubled” by the notion that marijuana businesses could be eligible for retroactive relief that stretches back into past tax years prior to rescheduling. “Many state-licensed marijuana operators participate in both medical and recreational markets, making it unclear how Treasury would distinguish business activities that qualify or do not qualify for federal tax treatment,” they said. “The shortcomings of relying on inconsistent state licensure are already evident. For example, having a state license to grow or sell marijuana in Oklahoma does not mean that the business acts lawfully. At the height of its medical marijuana program, Oklahoma had 9,178 licensed marijuana growing operations. While law enforcement has worked diligently to close down many of these operations that violated the law, they were all at one point state licensed marijuana businesses. There are documented instances where licensed operations funneled marijuana to the black market and engaged in other crimes, like money laundering and human trafficking. Many of these operations have also been owned and operated by Chinese nationals who have exploited state marijuana laws to commit crimes.” “Across the country, businesses follow a patchwork of laws to become a licensed marijuana business,” the lawmakers wrote in the new letter. Some may be more stringent than others, but it remains the case that state licensure alone does not guarantee legal compliance or justify eligibility for federal tax benefits.” Lankford and Arrington asking Bessent to answer a series of questions about the issue by June 29th: Can you further clarify the definition of “retrospective tax relief” in this context? How many prior tax years is the Treasury Department planning to consider for tax relief for marijuana businesses? How will the Treasury Department ensure that marijuana businesses that are potential candidates for tax relief have not violated any law, including the diversion of marijuana to the black market, human trafficking, and money laundering? What is the estimated reduction in federal revenue associated with providing marijuana businesses access to ordinary business deductions and credits? How would providing retrospective tax relief to marijuana businesses help American families? What would be the impact on annual federal deficits and the national debt to give certain marijuana business owners a newly created retroactive tax benefit? What statutory authority permits the federal government to give business owners who sold or manufactured a product against federal law a tax benefit? Separately on Wednesday, Lankford told Bessent at a Senate Finance Committee hearing that “in Oklahoma, we had a massive influx of Chinese illegal aliens that moved into our state and set up illegal grow operations for marijuana and started shipping it literally all over the country.” “It was a tragic thing to be able to watch what happened,” he said. In Oklahoma, we witnessed a massive influx of Chinese illegal aliens set up illegal marijuana grow operations and ship product all over the country. The human trafficking, labor trafficking, and sex trafficking that came with it was a tragedy. I look forward to working with… pic.twitter.com/8Z4eCM7SVr — Sen. James Lankford (@SenatorLankford) June 3, 2026 Last week, a group of congressional Democrats sent a latter asking Bessent and Internal Revenue Service (IRS) Chief Executive Officer Frank Bisignano to issue “prompt guidance” on tax issues for marijuana businesses in light of the Trump administration’s move to federally reschedule cannabis. “The absence of clear and timely guidance for the cannabis industry will leave taxpayers uncertain as to how they can benefit from the tax code—whether it is the treatment of ordinary and necessary business deductions or accessing of tax credits,” the lawmakers wrote. The U.S. Department of the Treasury and IRS said in April that they plan to soon issue guidance on tax issues for marijuana businesses stemming from rescheduling, but that hasn’t yet happened. In their announcement about forthcoming guidance, IRS and Treasury said they “expect DOJ’s action to have significant positive tax consequences for businesses in the medical marijuana industry.” “Accordingly, rescheduling generally removes section 280E as a bar to claiming deductions and credits for businesses that as a result of the Final Order no longer traffic in Schedule I or II controlled substances under the CSA,” they said. Because of the way the rescheduling action is being rolled out in phases, state-licensed marijuana companies that serve both the medical and recreational markets may only be able to immediately obtain tax relief for parts of their businesses. “Guidance is expected to clarify the ways in which, for businesses with multiple activities, section 280E applies only to those activities related to trafficking in Schedule I or II controlled substances (e.g., by apportioning expenses),” the tax agency and Treasury Department said. Blanche’s rescheduling order for DOJ said he “encourages” the treasury secretary “to consider providing retrospective relief from Section 280E liability for taxable years in which a state licensee operated under a state medical marijuana license.” But the Treasury and IRS announcement said that, at least for an initial transition rule, “rescheduling generally will be considered to first apply for a business’s full taxable year that includes the effective date of the Final Order, for the business’s activities that do not involve Schedule I or II controlled substances as a result of the Final Order.” The agencies did not specify when they expect to issue the forthcoming guidance. The post GOP Lawmakers Are ‘Troubled’ About Marijuana Businesses Getting Tax Relief Under Trump’s Rescheduling Move appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

I like your post. It is good to see you verbalize from the heart and clarity on this important subject can be easily observed... สมัครแทงบอล

VA marijuana push heats up; IA gov signs medical cannabis expansion; WY AG objects to rescheduling; PA medical cannabis in hospitals bill passes Subscribe to receive Marijuana Moment’s newsletter in your inbox every weekday morning. It’s the best way to make sure you know which cannabis stories are shaping the day. Get our daily newsletter. Email address: Leave this field empty if you're human: Your support makes Marijuana Moment possible… Hold on, just one second before you read today’s news. Have you thought about giving some financial support to Marijuana Moment? If so, today would be a great day to contribute. We’re planning our reporting for the coming months and it would really help to know what kind of support we can count on. Check us out on Patreon and sign up to give $25/month today: https://www.patreon.com/marijuanamoment / TOP THINGS TO KNOW Six Wisconsin Democratic gubernatorial candidates spoke at a forum hosted by a cannabis group—making pledges to advance marijuana legalization, protect hemp businesses and use their pardon powers if elected. The Virginia legislature’s Joint Commission to Oversee the Transition of the Commonwealth into a Cannabis Retail Market held its first meeting since Gov. Abigail Spanberger (D) vetoed bills to legalize recreational marijuana sales—with lawmakers discussing the possibility of putting the reform in budget legislation that’s due this month. Iowa Gov. Kim Reynolds (R) signed a bill to double the number of medical cannabis dispensaries that can be licensed, while also letting out-of-state residents register in the program if they have a certification from an Iowa healthcare provider. Wyoming Attorney General Keith Kautz (R) issued a formal “objection” to rescheduling marijuana under state law via a policy that would otherwise be automatically triggered by the Trump administration’s reclassification of cannabis at the federal level. The Pennsylvania House of Representatives passed a bill to allow terminally ill patients to use medical cannabis in hospitals, long-term care nursing facilities, assisted living residences and other healthcare centers. / FEDERAL The House bill to federally legalize marijuana got one new cosponsor for a total of 72. The House bill to allow marijuana businesses to list on stock exchanges got one new cosponsor for a total of four. The House bill to regulate hemp products got one new cosponsor for a total of seven. The House bill to delay the federal recriminalization of hemp THC products got two new cosponsors for a total of 36. / STATES Kentucky Gov. Andy Beshear (D) tweeted, “Medical cannabis has been found to decrease dependency on dangerous opioids and help people suffering reclaim their lives. We kept our promise to Kentuckians, and now every step of the medical cannabis process is complete as we deliver a safe alternative for pain relief.” Oklahoma Republican gubernatorial candidate Chip Keating said lawmakers have “grotesquely failed” to address illegal marijuana cultivation operations. New York lawmakers sent Gov. Kathy Hochul (D) legislation to address inversion of cannabis products from outside the state. South Carolina’s Senate majority leader said he doesn’t think the votes are there in his chamber to support a ban on hemp THC drinks. Alabama’s first medical cannabis dispensary is expected to open on Thursday. Washington, D.C. regulators cleared a business to get a medical cannabis dispensary license in the face of challenges concerning nearby daycare centers. Minnesota regulators extended the deadline to apply for a grants program supporting farmers, organizations and technical assistance providers entering the cannabis industry. California regulators sent updates on various cannabis issues. / LOCAL Los Angeles, California voters approved a ballot measure to impose taxes on unlicensed cannabis businesses. / INTERNATIONAL U.S. officials are investigating two more Mexican state governors over potential ties to drug cartels. / SCIENCE & HEALTH A study found that “THC usage among pediatric patients with positive [urine drug screens] did not increase with state legalization, nor did co-ingestion rates.” A study of mice found that “cannabidiol alleviates chemotherapy-induced cognitive decline and neuropathology.” / ADVOCACY, OPINION & ANALYSIS Disabled American Veterans published a post on military veterans’ therapeutic use of ibogaine. / BUSINESS Curaleaf Holdings, Inc. announced that its 1-for-3 reverse stock split will become effective on Friday. / CULTURE MMA fighter Daniel Rodriguez spoke to Joe Rogan about spending eight months in prison in Mexico over marijuana. Make sure to subscribe to get Marijuana Moment’s daily dispatch in your inbox. Get our daily newsletter. Email address: Leave this field empty if you're human: The post Wisconsin governor candidates pledge cannabis action if elected (Newsletter: June 4, 2026) appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Ragdoll Hit is a game where you win battles and collect coins. With those coins, you can unlock new characters with better armour and weapons, which will help you survive longer in the matches. Get enough coins to equip one of these weapons: bat, staff, kanabo, nunchaku, butterfly, katana, sword, holy blade, etc.

Stylish evenings become much more dynamic with premium Dwarka Escorts Service providing attractive companions who create classy vibes and create unforgettable luxury experiences.